Browse Category: Medical > Disease: Respiratory and Pulmonary System

Categories

[Search within category]

Tracheostomy Alarm for Accidental Decannulation

This invention describes a reusable alarm for sensing accidental tracheostomy decannulation.

Lineage-Negative Progenitor Cells Mobilize To Regenerate Lung Epithelium After Major Injury

This invention is a novel method of isolating a rare lineage-negative epithelial progenitor (LNEP) cell population and introducing it into the lungs of patients suffering from chronic fibrosis or acute injury.

Epithelial Growth Factor Receptor Antagonists Prevent Airway Mucus Production

This invention identifies a novel use for epidermal growth factor receptor (EGFR)antagonists in the treatment of airway mucus hypersecretion in patients, and includes invitro and in vivo screening assays.

Compositions And Methods For Treating And Diagnosing Asthma

To date, genome-wide expression analyses have not identified genetic biomarkers that are prognostic or predictive of therapeutic response to treatment for individual asthma patients, nor have they identified genetic biomarkers that distinguish subtypes of asthmatic patients.  In addition, no reliable non-genetic biomarkers with broad clinical applicability for prognostic or predictive responses to therapeutic treatment, or diagnostic of subtypes of asthma, have been identified.  Thus, as asthma patients seek treatment, there is considerable trial and error involved in the search for therapeutic agent(s) effective for a particular patient.  Such trial and error often involves considerable risk and discomfort to the patient in order to find the most effective therapy. Thus, there is a need for more effective means for determining which patients will respond to which treatment and for incorporating such determinations into more effective treatment regimens for asthma patients.

NOVEL MUCOLYTIC COMPOUNDS FOR TREATMENT OF PATHOLOGIC MUCUS IN AIRWAY DISEASES.

The incidence and complications arising from airway diseases are constantly increasing and chronic conditions of the airway significantly outnumber those of diabetes, cancer, heart disease combined. A quarter of the U.S. population are affected by airway diseases such as acute and chronic bronchitis, pneumonia, cystic fibrosis, asthma, chronic obstructive pulmonary disease (COPD), bronchiectasis, bronchiolitis, ventilator-associated airway mucus hyper-secretion, and acute and chronic sinusitis. Mucus overproduction and hypersecretion have been implicated to play a key role in these airway diseases.  However, mucus pathology is very poorly understood and hence recent advances have not been sufficient to develop effective treatments. Existing mucolytic drugs provide only moderate relief and have a number of limitations such as weak potency, volatility, bad smell in addition to side effects such as nausea, rash and sores. There is a need to address the large unmet need for novel mucolytic therapies for a wide range of acute and chronic airway disease.

Integrin Avb8 Neutralizing Antibody

Brief description not available

METHOD FOR REDUCING SURFACTANT INACTIVATION IN PULMONARY SURFACTANT THERAPY

Human lung surfactant is a complex mixture of lipids and proteins that reduces surface tension in the lung, enabling normal breathing. Lack of effective surfactant results in Respiratory Distress Syndrome (RDS), a potentially fatal condition seen in premature infants and in adults with lung infection or trauma. While replacement lung surfactant (RLS) therapy has revolutionized neonatal RDS treatment, it is relatively ineffective in adults. Even with neonatal RDS, up to 30% of infants do not respond to RLS therapy. This failure in RLS therapy has been attributed, at least in part, to inactivation of the replacement lung surfactant in distressed lungs.Researchers at the University of California, San Francisco, have discovered that inactivation of surfactants by endogenous substances present in the lung can be significantly reduced by administration of either ionic or nonionic polymers. Ionic polymers are particularly effective, and have the advantage that lung epithelial cells produce them endogenously. The polymers may therefore be useful in the design of second-generation surfactants for use in RLS.

  • Go to Page:

ADDRESS

UCSF
Office of Innovation, Technology & Alliances

3333 California Street, Suite S-11,
San Francisco,CA 94143-1209